丝状病毒的出现与疫苗研发：旅行医学中医疗从业者的视角。
Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892-3017, USA.
出版信息
Travel Med Infect Dis. 2011 May;9(3):126-34. doi: 10.1016/j.tmaid.2010.05.003. Epub 2010 Jun 26.
Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90% case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.
最近在欧洲和美国发生的病毒性出血热病例报告引起了人们对滤过性病毒可能传入非流行地区的关注。这种新出现的威胁令人担忧，因为全球航空旅行增加，中非和东非的旅游业兴起，以及军事部队向传染病爆发地区的更大分散。马尔堡病毒（MARV）和埃博拉病毒（EBOV）与涉及高死亡率（25-90%病死率）的严重出血热爆发有关。MARV 和 EBOV 分别于 1967 年和 1976 年首次被发现，是 Filoviridae 科中唯一已知的病毒，也是世界上最致命的病原体之一。本文重点介绍与旅行医学中的医疗保健从业者相关的信息，包括滤过性病毒感染的流行病学和临床特征，以及开发滤过性病毒疫苗的努力。
Zotero 插件